Mounjaro UK - Cheapest Price £124.99 | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Mounjaro UK - Cheapest Price From £124.99

Get Mounjaro at the cheapest UK price from £124.99 with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£145.00 From £124.99 £20 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

Start Consultation

Understanding Mounjaro UK: Clinical Evidence and Patient Access

Mounjaro UK availability has transformed weight management options for patients across Britain since its MHRA approval for chronic weight management in adults with obesity or overweight alongside related health conditions. As a UK-registered pharmacy with GPhC superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing clinical services, we provide genuine tirzepatide injections at £124.99 following comprehensive online assessment by UK prescribers. Clinical trials demonstrate that Mounjaro delivers superior weight reduction outcomes compared to other GLP-1 receptor agonists, making it a clinically significant option for eligible patients[1].

What Is Mounjaro UK and How Does It Work?

Mounjaro UK refers to the MHRA-licensed tirzepatide injection prescribed for chronic weight management in adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia[1]. Unlike single-receptor agonists, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a dual mechanism that enhances insulin secretion, suppresses glucagon release, and significantly reduces appetite[2].

The dual-agonist mechanism distinguishes Mounjaro from semaglutide-based treatments. By engaging GIP receptors alongside GLP-1 pathways, tirzepatide produces more pronounced effects on satiety signalling in the hypothalamus and delays gastric emptying more effectively than single-receptor medications[2]. Clinical observations show patients typically experience reduced hunger within days of initiating therapy, with progressive weight reduction over subsequent months when combined with dietary modification and increased physical activity.

Every Mounjaro UK prescription requires clinical assessment by a UK-registered prescriber who evaluates medical history, current medications, contraindications, and suitability for tirzepatide therapy. At Cured Pharmacy, our clinical team completes this assessment online in under three minutes, ensuring patients receive appropriate prescribing decisions before dispensing genuine UK-licensed medication.

Mounjaro UK Clinical Trial Evidence and Efficacy

The SURMOUNT-1 trial demonstrated that Mounjaro UK (tirzepatide) produced average weight reductions of 15.0% with the 5 mg dose, 19.5% with the 10 mg dose, and 20.9% with the 15 mg dose over 72 weeks in adults with obesity but without diabetes[1]. These results significantly exceeded placebo outcomes and surpassed head-to-head comparisons with semaglutide 1.0 mg in separate analyses, establishing tirzepatide as one of the most effective pharmacological interventions for weight management currently available in the UK.

The SURMOUNT-2 trial specifically evaluated Mounjaro in patients with type 2 diabetes and obesity, showing average weight reductions of 12.8% with the 10 mg dose and 14.7% with the 15 mg dose alongside meaningful improvements in glycaemic control[3]. These dual benefits make tirzepatide particularly valuable for UK patients managing both conditions simultaneously, though prescribers must carefully assess cardiovascular history and pancreatitis risk before initiating treatment.

Long-term safety data from the SURMOUNT programme showed gastrointestinal adverse effects (nausea, diarrhoea, constipation) as the most common side effects, typically mild to moderate and diminishing over time[1][3]. Serious adverse events remained low across all dose groups, though patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 cannot use tirzepatide due to contraindications identified in preclinical studies.

Real-World Mounjaro UK Patient Outcomes

Post-marketing surveillance and real-world evidence from UK prescribing data increasingly support the clinical trial findings, with patients achieving substantial weight reduction when adhering to prescribed dosing schedules and lifestyle modifications. Our clinical team at Cured Pharmacy observes that patients who maintain regular follow-up assessments and titrate doses appropriately tend to experience better tolerability and sustained weight loss over extended treatment periods, though individual responses vary considerably based on metabolic factors, adherence, and baseline characteristics.

Mounjaro UK Dosing Schedule and Administration

Mounjaro UK treatment begins with a 2.5 mg subcutaneous injection once weekly for four weeks, serving as an initial dose to improve gastrointestinal tolerability while initiating therapeutic effects[4]. After this lead-in period, the dose escalates to 5 mg weekly, with further increases to 7.5 mg, 10 mg, 12.5 mg, and ultimately 15 mg at four-week intervals based on individual response and tolerability, as determined by the prescribing clinician.

Patients self-administer Mounjaro injections subcutaneously into the abdomen, thigh, or upper arm using the pre-filled KwikPen device, which requires no dose preparation or needle attachment beyond removing the cap. Injection sites should rotate weekly to minimise injection-site reactions, and the medication must remain refrigerated between 2°C and 8°C until use, though it may be kept at room temperature (up to 30°C) for up to 21 days if needed[4].

Dose escalation decisions for Mounjaro UK prescriptions depend on weight loss progress, side effect profile, and clinical response assessed during follow-up consultations. Some patients achieve their weight management goals at lower maintenance doses (5 mg or 7.5 mg weekly), while others require titration to 10 mg or 15 mg for optimal results. UK prescribers evaluate each patient's trajectory individually rather than applying universal protocols, ensuring personalised treatment aligned with clinical guidelines and patient preferences.

Treatment Active Ingredient Frequency Starting Price
Mounjaro Tirzepatide Weekly injection from £145.00
Wegovy Semaglutide Weekly injection from £89.00
Saxenda Liraglutide Daily injection from £68.00
Wegovy Oral Tablets Semaglutide Daily tablet from £83.00
Xenical Orlistat 120mg Three times daily from £49.99
Alli Orlistat 60mg Three times daily from £49.99

Mounjaro UK Pricing and Prescription Access at Cured Pharmacy

Cured Pharmacy supplies Mounjaro UK at £124.99 per prescription following successful clinical assessment by our UK-registered prescribing team, with an additional £20 discount available on first orders using code Weightlossnew. This transparent pricing includes the clinical consultation, prescriber review, genuine MHRA-licensed medication, and discreet delivery to your UK address, with no hidden fees or subscription requirements.

Accessing Mounjaro UK through our pharmacy requires completing an online medical questionnaire that covers your weight management history, current medications, relevant medical conditions, and treatment goals. Our UK prescribers (registered with the General Pharmaceutical Council) review each submission individually, typically within hours, and approve prescriptions only when clinically appropriate based on MHRA licensing criteria and NICE guidance for weight management interventions[5].

We guarantee the lowest UK pricing for genuine Mounjaro while maintaining full regulatory compliance and clinical safety standards. Every medication dispensed carries batch-specific verification, proper storage documentation, and originates from UK-licensed wholesalers, ensuring patients receive authentic tirzepatide rather than counterfeit or unlicensed products increasingly prevalent through unregulated online sources.

Why Choose Cured Pharmacy for Mounjaro UK

As a fully registered UK pharmacy (GPhC 9012511) with superintendent pharmacist Tarun Kumar overseeing all clinical operations, we provide comprehensive support throughout your Mounjaro treatment journey. Our prescribing team remains available for follow-up consultations, dose adjustment discussions, and side effect management guidance, ensuring continuity of care that matches traditional pharmacy services while offering the convenience of online access and competitive pricing that reflects our efficient operational model.

Mounjaro UK Side Effects and Safety Considerations

The most common side effects associated with Mounjaro UK treatment include nausea (reported by up to 30% of patients in clinical trials), diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain[1][3]. These gastrointestinal effects typically emerge during dose escalation phases and generally diminish in severity as treatment continues, though some patients require dose reduction or extended time at lower doses to maintain tolerability.

Serious but rare adverse effects require immediate medical attention and include signs of pancreatitis (severe persistent abdominal pain radiating to the back), symptoms of thyroid tumours (neck lump, hoarseness, difficulty swallowing), severe allergic reactions, acute kidney injury (particularly in patients experiencing severe vomiting or diarrhoea), and hypoglycaemia when used alongside insulin or sulfonylureas[4]. UK prescribers screen for risk factors during initial assessment and provide clear guidance on recognising these warning signs.

Mounjaro UK carries contraindications for patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous serious hypersensitivity to tirzepatide, and should be used with extreme caution in patients with severe gastrointestinal disease, history of pancreatitis, or diabetic retinopathy[4]. Pregnant or breastfeeding women cannot use tirzepatide, and women of childbearing potential should use reliable contraception during treatment and for at least four weeks after discontinuation.

Mounjaro UK Compared to Alternative Weight Loss Treatments

When evaluating Mounjaro UK against semaglutide-based treatments like Wegovy, head-to-head trial data suggests tirzepatide produces superior average weight reduction, with the 10 mg and 15 mg doses of Mounjaro typically exceeding the weight loss achieved with semaglutide 2.4 mg[1][6]. However, individual responses vary considerably, and some patients may experience better tolerability or outcomes with semaglutide, making treatment selection a personalised clinical decision rather than a universal recommendation.

Liraglutide (Saxenda) represents an earlier-generation GLP-1 receptor agonist requiring daily injections and producing more modest weight reductions (average 5-8% body weight) compared to weekly tirzepatide or semaglutide options[6]. While Saxenda remains clinically effective and appropriate for many patients, particularly those preferring daily dosing or having contraindications to dual-agonist therapy, Mounjaro UK and Wegovy have largely superseded it as first-line pharmacological interventions in current UK weight management protocols.

Orlistat-based treatments (including Xenical and Alli) work through an entirely different mechanism—blocking dietary fat absorption rather than affecting appetite or metabolic hormones—and produce average weight reductions of 3-5% when combined with reduced-calorie diets[6]. These medications suit patients unable or unwilling to use injectable therapies, though the gastrointestinal side effects associated with unabsorbed fat and the more modest efficacy profile make GLP-1 and dual-agonist treatments preferable for patients seeking maximum weight reduction and able to tolerate injection-based therapy.

Choosing Between Mounjaro UK and Other Options

UK prescribers consider multiple factors when recommending between Mounjaro and alternative weight management medications, including baseline BMI, presence of type 2 diabetes, cardiovascular risk profile, previous treatment responses, injection frequency preferences, cost considerations, and individual side effect tolerance. Our clinical team at Cured Pharmacy discusses these factors during consultation, ensuring patients understand the evidence base for each option and participate actively in treatment selection aligned with their goals and clinical circumstances.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
  2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.
  3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of tirzepatide in adults with overweight or obesity: the SURMOUNT-2 trial. Nature Medicine, 29(11), 2919-2928.
  4. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk.
  5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity. NICE Technology Appraisal Guidance.
  6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Is Mounjaro UK available without a prescription?
No, Mounjaro UK is a prescription-only medication that requires clinical assessment and approval by a UK-registered prescriber before dispensing, ensuring safe and appropriate use for eligible patients.
How quickly does Mounjaro UK produce weight loss results?
Most patients notice reduced appetite within the first week, with measurable weight reduction typically beginning within 4-8 weeks and progressive loss continuing throughout the dose escalation period over subsequent months.
Can I use Mounjaro UK if I have type 2 diabetes?
Yes, Mounjaro UK is licensed for weight management in patients with type 2 diabetes and obesity, with clinical trials showing significant benefits for both weight reduction and glycaemic control in this population.
What is the difference between Mounjaro UK and Wegovy?
Mounjaro contains tirzepatide (a dual GIP/GLP-1 receptor agonist) while Wegovy contains semaglutide (a GLP-1 receptor agonist only), with clinical data suggesting Mounjaro typically produces greater average weight reduction.
How long do I need to stay on Mounjaro UK treatment?
Treatment duration varies individually based on weight loss goals, clinical response, and ongoing need for weight management support, with many patients continuing long-term to maintain weight reduction achieved during initial treatment phases.
Does Mounjaro UK cause serious side effects?
Serious side effects are rare but can include pancreatitis, thyroid tumours, severe allergic reactions, and acute kidney injury, though most patients experience only mild to moderate gastrointestinal effects that improve over time.
Can I buy Mounjaro UK for same-day delivery?
Following successful prescriber approval, Cured Pharmacy offers next-day delivery across the UK in discreet packaging, ensuring prompt access to your prescribed medication with full tracking and delivery confirmation.
Is the Mounjaro UK price at Cured Pharmacy the cheapest available?
Yes, we guarantee the lowest UK price for genuine Mounjaro at £124.99, with an additional £20 discount on first orders using code Weightlossnew, while maintaining full GPhC registration and clinical safety standards.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 26 July 2026